Treatment of AD mice with synthetic LXR agonists, including TO901317 and GW3965, consistently improves cognitive performance and can decrease amyloid burden [41–46], and we have shown that ABCA1 is required for the beneficial effects of GW3965 in AD mice [42]. This evidence concerns the gene ABCA1 and Alzheimer disease.